Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

CNC

Market Inference Overview -- CNC Stock

Centene logged a -0.3% change during today's afternoon session, and is now trading at a price of $34.24 per share. The S&P 500 index moved 1.0%. CNC's trading volume is 5,453,919 compared to the stock's average volume of 14,072,971.

Centene trades -4.88% away from its average analyst target price of $36.0 per share. The 17 analysts following the stock have set target prices ranging from $24.0 to $70.0, and on average have given Centene a rating of hold.

If you are considering an investment in CNC, you'll want to know the following:

  • Centene's current price is -59.5% below its Graham number of $84.61, which implies the stock has a margin of safety

  • Centene has moved -46.5% over the last year, and the S&P 500 logged a change of 16.0%

  • Based on its trailing earnings per share of 4.12, Centene has a trailing 12 month Price to Earnings (P/E) ratio of 8.3 while the S&P 500 average is 29.3

  • CNC has a forward P/E ratio of 4.9 based on its forward 12 month price to earnings (EPS) of $7.04 per share

  • Its Price to Book (P/B) ratio is 0.61 compared to its sector average of 3.19

  • Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, and commercial organizations in the United States.

  • Based in Saint Louis, the company has 60,500 full time employees and a market cap of $16.82 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS